Cell and Gene Therapy Logistics From Vein to Vein

Cell and gene therapy logistics is the planning and control of how patient cells, viral vectors and finished therapies move between collection sites, manufacturers and treatment centers. Every move has to happen at the right temperature, inside a fixed time window and with an unbroken link to the patient or donor. For an autologous CAR-T product, that means one patient's cells leave the hospital, travel to a manufacturing site, become a personalized dose and travel back to the same patient. A mix-up, a missed flight or a dry shipper that runs warm can cost that patient a treatment slot.

Conventional pharma logistics moves batches of identical product into inventory. The cell and gene therapy supply chain moves single units that are often irreplaceable, scheduled around a patient's clinical status, with temperatures that run from refrigerated to deep cryogenic within one journey. This guide explains how those flows work, which rules apply in the US and the EU, how the products are shipped and what to check before you choose a partner.

What is cell and gene therapy logistics?

It is the part of the advanced therapy supply chain that covers collection pickups, transport, storage in transit, identity tracking and documentation from donor to recipient. Teams shorten it to CGT logistics or cell & gene logistics, and the scope is the same in each case. Every handoff has to protect both the viability of the material and its identity.

Two product groups drive the work. Cell therapy logistics deals with living cells, such as CAR-T cells, stem cells or donor-derived cell banks. Gene therapy logistics deals with products that deliver genetic material, such as viral vector products given directly to the patient. The FDA describes both routes. Some gene therapies modify cells outside the body and return them to the patient, while others make the change inside the body. The first route behaves like cell therapy logistics. The second behaves more like frozen biologics distribution, with very small volumes per patient and strict use-by limits after receipt. A gene therapy supply chain built on viral vectors therefore has fewer handoffs than an autologous loop, but it still depends on precise frozen and refrigerated transitions at the site.

Autologous and allogeneic flows

The biggest design choice is whose cells the therapy uses. Autologous products start with the patient's own cells. Allogeneic products start with donor cells and can be manufactured ahead of demand. The table compares how that choice changes the logistics plan.

Autologous programs carry the heavier logistics load because every shipment is a one-off with a named patient at the end of it. Allogeneic programs look closer to conventional distribution, yet they still need cryogenic storage, donor-to-recipient tracking and controlled receipt at the site.

Inside the vein-to-vein journey

What is the vein-to-vein supply chain?

It is the full loop from the moment cells leave a patient's vein at collection to the moment the finished therapy goes back into that patient's vein at infusion. Some teams call it needle to needle. Each step has its own owner, timing and temperature, and the logistics plan has to connect them without gaps. Good cell therapy supply chain management treats the loop as one process rather than as a series of separate shipments.

1. Scheduling. The treatment center, the manufacturer and the logistics provider agree on a collection date and a manufacturing slot before the patient is collected, then book the courier and flights around both.

2. Apheresis collection. Cells are collected at an apheresis center, labeled with the patient's identifiers and a distinct identification code, and packed to the sponsor's specification.

3. Transport to manufacturing. Fresh starting material travels under refrigerated or controlled ambient conditions to the manufacturing site, or it is cryopreserved near the collection site and shipped frozen.

4. Manufacturing and release. The cells are modified, expanded, tested and released against set criteria. Release documents travel with the dose or ahead of it.

5. Return to the treatment center. The cryopreserved dose ships in a liquid nitrogen dry shipper to the hospital cell lab or pharmacy, where staff confirm identity on receipt.

6. Infusion. The site stores the dose under its label conditions, thaws it and infuses it at the scheduled time.

For the CAR-T version of this loop, including point-of-care and centralized manufacturing models, see our CAR-T supply chain and logistics guide.

Fresh or frozen starting material

Fresh starting material is usually the most time-sensitive leg because its hold limit is set by the manufacturer's own stability data, and the logistics plan has to work backward from that number. As one example, a 2025 study in Scientific Reports found that leukapheresis products for an investigational CAR-T process stayed most stable for up to 73 hours at 2-8 °C, compared with storage at 15-25 °C. The authors also cited stability data for an approved CAR-T product in which viability fell faster at room temperature than at refrigerated temperature. Treat those figures as one program's evidence, not as a general limit.

Other programs avoid the race by cryopreserving the apheresis material close to the collection site and shipping it frozen. That separates the collection date from the manufacturing slot, at the cost of an extra processing step that must itself be controlled and validated. If your material is live cells shipped unfrozen in culture medium, our live cell shipment guide covers packaging and timing for that case.

Chain of identity and chain of custody

Chain of identity is the permanent link between a patient or donor and their cells at every stage. Chain of custody is the documented record of who held the material, where and when. A third term, chain of condition, is the temperature and handling record that proves the material stayed within specification. Logistics teams need all three, held in a record that sponsors, sites and auditors can all read.

In the US, the tracking rule for cell and tissue products is 21 CFR 1271.290. Any establishment that handles an HCT/P during manufacture must be able to track it from the donor to the consignee or final disposition, and back again. Each product needs a distinct identification code that relates it to the donor and its records, and that code may not include the person's name, Social Security number or medical record number. Many programs build their labels on ISBT 128, the global standard managed by ICCBBA for the terminology, identification, coding and labeling of medical products of human origin.

In practice, identity controls show up at each handoff. The courier checks the code at pickup, the manufacturing site matches it against the shipping record, and the treatment center matches the patient identifiers on the cassette and bag on receipt. FDA labels for approved CAR-T products write that last check into their handling instructions. The Yescarta label, for example, tells the site to match the patient's identity with the identifiers on the cassette and infusion bag upon receipt.

How are cell and gene therapies shipped?

They ship in packaging matched to the stage and to the product's own data. Many fresh starting materials travel refrigerated or at controlled ambient temperature, cryopreserved cell products travel in liquid nitrogen dry shippers, and many viral vector gene therapies travel frozen. Each shipment carries a temperature logger, usually a location tracker, and the identity and release documents the receiver needs. The exact temperature always comes from the label, the protocol or the stability data, never from a generic category.

Temperature ranges by stage

Published FDA labels show how much the numbers vary, even within one product class. The table pulls stage temperatures from current labels on DailyMed and from the stability study cited above.

The lesson is that cryogenic is not a single number. A dry shipper that holds at or below -150 °C meets all three CAR-T conditions above, but a site freezer at -120 °C meets only some of them, and a gene therapy shipped frozen may switch to refrigerated storage on arrival with a hard use-by clock. That range explains why the cold chain logistics cell and gene therapy programs need is different from vaccine or standard biologics distribution. Build the shipping specification from the label or the clinical protocol for each product.

Dry shippers, dry ice and dangerous goods rules

Dry shippers provide the cryogenic transport cell and gene therapy products need without free liquid in the package. They are vacuum-insulated dewars with an absorbent that holds liquid nitrogen. Under the IATA Dangerous Goods Regulations, a correctly prepared dry shipper falls under Special Provision A152 and travels as not restricted. As Weill Cornell's EHS dry shipper guidance summarizes it, the shipper must not allow pressure to build up, must not release liquid nitrogen in any orientation, and the air waybill must read "Not restricted, as per Special Provision A152". The same guidance notes that dry shippers holding Category A or B biological materials may need additional packaging, so classify the contents as a separate step and confirm the wording against the DGR edition in force on the shipping date.

Frozen gene therapies in the -60 °C to -80 °C range can travel on dry ice instead, and dry ice is itself regulated for air transport. In the US, 49 CFR 173.217 requires packaging that vents carbon dioxide gas, the net mass of dry ice marked on the package, and advance arrangements with the aircraft operator. A gene therapy courier carrying a frozen vector kit to a hospital pharmacy has to meet those rules and the product's receipt instructions at the same time. Preparation, charging and return of dewars are covered in our guide to cryogenic transport with LN2 dry shippers, and the evidence behind packaging choices is covered in gene therapy shipping and packaging validation.

Scheduling, orchestration platforms and real-time monitoring

Many autologous programs run on a scheduling and orchestration platform that books manufacturing slots, triggers courier orders and holds chain of identity records in one place. The logistics provider either works inside that platform or connects to it, so pickup windows, flight bookings and milestone status flow back to the sponsor without manual re-entry. When the platform and the courier's own system disagree, someone has to own the correction, and that owner should be named in the quality agreement.

Monitoring closes the loop. A temperature logger records the chain of condition, a GPS tracker shows location, and an operations team watches both in real time so it can act before an excursion or a missed connection becomes a lost dose. In cold chain logistics in cell therapy, the useful question for any provider is who watches the data at 3 a.m. and what that person is authorized to do about it.

Regulatory frame for advanced therapies logistics

Logistics for cell and gene therapy has to follow rules that depend on the jurisdiction and on how each product is classified. Check every lane against its origin, its destination and the product's own approval or protocol. The points below are the anchors most plans refer to, and none of them replaces the sponsor's regulatory assessment.

United States

FDA regulates human cells and tissues intended for implantation, transplantation, infusion or transfer into a recipient as HCT/Ps under 21 CFR 1271.3(d). Products that are minimally manipulated, intended for homologous use and meet the other criteria in 1271.10 are regulated solely under section 361 of the Public Health Service Act. Products that do not meet those criteria, including the CAR-T therapies on FDA's list of approved cellular and gene therapy products, are regulated as biological products. For those, 21 CFR 1271.1(b)(2) requires the part 1271 donor-eligibility and current good tissue practice procedures in addition to the drug and biologics cGMP rules.

Two good tissue practice sections matter directly to logistics. Section 1271.265 requires shipping containers designed to protect the product from contamination and shipping conditions set for each type of HCT/P. It also requires documented receipt, predistribution shipment and distribution activities, including the date, the quantity and the identity of the consignee. Section 1271.290 sets the tracking requirement described earlier.

Commercial site requirements have also shifted. On June 27, 2025, FDA eliminated the Risk Evaluation and Mitigation Strategies for approved autologous CAR-T therapies, which had required dispensing hospitals and clinics to be specially certified and to have immediate on-site access to tocilizumab. Sponsors may now work with a wider set of treatment sites, and each new site is a new lane to plan and qualify.

European Union

In the EU these products are advanced therapy medicinal products, or ATMPs. They are governed by Regulation (EC) No 1394/2007 and assessed with input from EMA's Committee for Advanced Therapies. Manufacturing follows the Commission's GMP guidelines specific to ATMPs in EudraLex Volume 4, Part IV. Distribution falls under EU Good Distribution Practice, which EMA describes as the minimum standards a wholesale distributor must meet. For advanced therapies logistics that crosses the Atlantic, the plan has to satisfy both sets of rules and the import requirements of every country on the route.

Customs for human-derived material

International CGT logistics adds customs and permit checks for material of human origin. In the US that can raise CDC import permit questions for some human-derived materials, which we explain in our guide to importing human-derived materials into the United States. Paperwork filed before departure reduces the chance of a border hold while a dry shipper's hold time runs down. Mercury's licensed customs brokerage team completes pre-advisory documentation before a cold chain shipment moves and uses saved commodity profiles for repeat lanes.

Clinical vs commercial supply

Clinical programs treat small numbers of patients across many sites, often in several countries, under protocols that can change between study phases. Flexibility matters more than unit cost, and training site staff on receipt and identity checks is a large part of the workload. Commercial programs run higher and steadier volumes to a defined network of treatment centers, with approved label conditions that the shipping specification must match. Commercial lanes need repeatable performance, capacity reserved ahead of demand and written agreements on who does what.

The move from clinical to commercial is where gaps tend to appear. A courier network that served ten trial sites may not cover fifty treatment centers, and a dry shipper fleet sized for a study can run short at launch. Plan the commercial network while the pivotal study is still running, and qualify new lanes before they carry patient material. Our clinical trials logistics page explains how Mercury supports sponsors during the study phase.

Common challenges in CGT logistics

What are the challenges involved in cell and gene logistics?

The main challenges are tight time windows, cryogenic handling, identity risk, customs delays for human-derived material, limited capacity and the need for contingency plans that work at short notice. Each one hits harder than in conventional pharma because a lost autologous dose cannot be replaced from stock.

Time windows. Fresh material hold limits, the manufacturing slot and the patient's treatment schedule all have to line up. A cancelled flight or a weekend closure at the receiving lab can break that chain, so build buffer time into each leg and confirm receiving hours before pickup.

Cryogenic handling. Dry shippers need correct charging, a known hold time and handling that keeps them upright where the design requires it. Empty shippers also have to come back, be cleaned and be recharged, which affects fleet size.

Customs and screening. Human-derived material can trigger document reviews and holds. Agree in advance whether each shipment may be X-rayed or opened, how that is communicated to authorities and what happens if an officer insists on inspection.

Capacity. Manufacturing slots, trained couriers, cryogenic shippers and flight space are all limited. Reserve them ahead of patient demand instead of booking each shipment from scratch.

Contingency planning. Each lane needs a backup route, a backup carrier and named escalation contacts with authority to decide. Pre-agree what happens after an excursion, who quarantines the material and who decides whether it can still be used. For the most critical legs, an onboard courier who travels with the shipment removes a handoff from the plan.

Selecting and working with a logistics partner

How do you choose a cell and gene therapy logistics partner?

Choose a cell and gene therapy logistics partner by testing how it handles your specific lanes, temperatures and identity controls rather than by reading capability lists. Ask for evidence on each point below and confirm it with a test shipment before the first patient. Cell therapy logistics solutions differ most in how they handle exceptions, so spend most of the review there.

• Experience with your exact origin and destination pairs, including weekend and holiday coverage.

• Qualified packaging for every temperature in your protocol, with data for the hold time you need. It is fair to ask how their cryogenic process lines up with ISO 21973, the international standard on transportation of cells for therapeutic use.

• Chain of identity and custody records that map to your codes and your orchestration platform.

• Real-time temperature and location monitoring with a staffed 24/7 team and a defined escalation path.

• Customs capability for human-derived material, including documents filed before departure.

• Contingency options such as backup routing, liquid nitrogen recharging and onboard courier service.

• A quality agreement that states who decides on excursions and who keeps which records.

• Capacity to grow from clinical to commercial volumes without changing the qualified process.

A gene therapy supply chain partner should also understand frozen to refrigerated transitions at the site, since some vector products change storage temperature on receipt. A cell therapy supply chain provider should show how it handles a failed collection, a rescheduled manufacturing slot and a dose that cannot be infused on the planned day.

Where Mercury fits

Mercury is a healthcare and life science logistics company that has been shipping since 1984, and cell and gene therapy is part of its specialty cold chain work. Our cell and gene therapy shipping service moves cryogenic materials in dewars and dry shippers that are tested and validated, with temperature monitoring throughout transit, GPS-based chain of custody management, GDP-compliant handling and customs guidance on permits and documentation. For CAR-T cell therapy shipping, Mercury uses cryogenic dewar containers with temperature monitoring devices and GPS trackers, provides chain-of-custody documentation and partners with cryogenic storage facilities. Clinical programs work with a dedicated representative and get real-time visibility and milestone notifications, and the logistics team is available 24/7. When a lane needs a person with the shipment, Mercury's onboard courier service carries temperature-sensitive cargo door to door with cold chain packaging.